The medical journal that published the pivotal clinical trial used to approve the drug Tavneos for a rare autoimmune disease has formally retracted that study — and federal regulators have proposed withdrawing the drug's approval entirely.
The New England Journal of Medicine retracted the 2021 paper detailing the pivotal ADVOCATE clinical trial, citing concerns that patient outcome data were altered and that some researchers had been unblinded during the trial. The retraction was requested by two of the trial's academic authors after an FDA investigation found that results for nine patients had been changed. According to the retraction note, the primary endpoint assessments for nine patients were readjudicated after database lock and trial unblinding, without the knowledge of the two requesting authors — and this was not disclosed in the published article.
The FDA formally proposed withdrawal of Tavneos on April 27, 2026, on two grounds: lack of substantial evidence of effectiveness in light of the data manipulation, and the application containing untrue statements of material fact.
The most important message for patients currently taking Tavneos: do not stop this medication without speaking to your physician. As of this writing, the FDA has not issued a recall or ordered Tavneos off the market, and patients may still be deriving clinical benefit from the drug.
Why This Matters
ANCA-associated vasculitis is a rare and serious autoimmune disease that causes inflammation in small and medium blood vessels — damaging kidneys, lungs, and other organs. Without adequate treatment, it can cause kidney failure, respiratory failure, and death. Most patients rely on a combination of immunosuppressive drugs, typically including rituximab or cyclophosphamide alongside glucocorticoids (steroids).
Tavneos (avacopan) was approved in October 2021 as an adjunct therapy specifically to reduce the corticosteroid burden — steroids carry serious long-term side effects including bone loss, diabetes, and immune suppression. If Tavneos actually reduces steroid exposure while maintaining disease control, that is a meaningful clinical benefit.
The question that the retraction puts back on the table is whether the ADVOCATE trial actually proved that. The NEJM retraction is not a small correction. It is the strongest step a medical journal can take: it formally withdraws the article and no longer stands behind it.
What We Know So Far
The retraction was published on June 29, 2026, and was requested by two of the four ADVOCATE trial authors — Dr. David Jayne and Dr. Peter Merkel, the academic physicians who led the study. The NEJM editors concluded that the conduct was inconsistent with proper research standards and retracted the article.
The EMA's human medicines committee simultaneously recommended revoking Tavneos' marketing authorization in the European Union, concluding that the drug's benefits are no longer proven to outweigh its risks after reviewing the totality of available data and new information about how the study data were handled.
Additionally, the FDA's March 2026 drug safety communication identified 76 cases of drug-induced liver injury with reasonable evidence of a causal association with avacopan, including 74 serious outcomes, 54 hospitalizations, and 8 deaths.
Despite the mounting pressure, Amgen has resisted voluntary recall and is preparing for an FDA formal hearing scheduled for July 2026. Amgen has commissioned the Duke Clinical Research Institute to perform an independent, fully blinded re-adjudication of the ADVOCATE study's primary endpoints, intending to present these findings to federal regulators.
Where the Impact Is Greatest
Patients currently taking Tavneos who should immediately contact their physician include:
- Adults with granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA) — the two main forms of ANCA-associated vasculitis — who were prescribed Tavneos as part of their regimen
- Patients who switched from standard corticosteroid therapy to Tavneos specifically to reduce steroid side effects
- Patients who have had liver function abnormalities while on Tavneos — a signal that now warrants more urgent clinical attention given the FDA's hepatotoxicity communication
What Doctors and Experts Say
Vasculitis specialists are emphasizing the same message to patients: "If patients come to you, reassure them, and remind them that no one should change or stop any treatment on their own. That conversation belongs with their own doctor."
Nephrologists and rheumatologists managing ANCA vasculitis patients are now navigating a difficult clinical situation: a drug that was approved based on data now characterized as manipulated, whose benefits in individual patients are real in some cases, but whose regulatory future is deeply uncertain.
The critical near-term clinical decision — whether to continue Tavneos, reduce the dose, or transition to an alternative regimen — should be individualized based on disease severity, current disease control, and the patient's specific risk-benefit profile. That conversation requires the patient's specialist.
What the Evidence Shows — and What It Does Not
MedicalDaily Evidence Check
- Drug : Tavneos (avacopan); Amgen
- Approved indication : Adjunctive treatment of severe active ANCA-associated vasculitis (GPA and MPA) in combination with standard therapy
- Pivotal trial : ADVOCATE (331 patients, 2021) — retracted June 29, 2026
- Reason for retraction : Post-lock, post-unblinding readjudication of 9 patients' outcomes without author knowledge or disclosure
- FDA action : Proposed withdrawal April 27, 2026; formal hearing scheduled July 2026
- EMA action : Recommended revoking EU marketing authorization
- Additional safety concern: 76 cases of drug-induced liver injury linked to avacopan; 8 deaths
- What this does not mean : That Tavneos provides zero benefit to any individual patient
- What readers should know : Do not stop Tavneos without physician guidance; the FDA has not yet formally completed withdrawal proceedings; alternative agents exist and can be discussed with your specialist
Who Faces the Greatest Risk?
Patients at the highest risk from the current regulatory situation are:
- Those who have been taking Tavneos for liver function monitoring — who should ensure their most recent liver enzyme values are current
- Patients who were prescribed Tavneos as a corticosteroid-sparing strategy and are now asking whether they should return to higher steroid doses in consultation with their physician
- Patients who would lose disease control if Tavneos is abruptly discontinued — this is the specific population for whom stopping without medical supervision is most dangerous
Symptoms and Warning Signs to Watch For
Any patient currently on Tavneos who develops the following should contact their physician immediately:
- Jaundice (yellowing of skin or eyes)
- Dark urine
- Severe fatigue or nausea
- Upper right abdominal pain
- Fever without other explanation
These signs may indicate drug-induced liver injury — the serious adverse event the FDA's safety communication highlighted.
What You Can Do Now
- Do not stop Tavneos without calling your nephrologist or rheumatologist. Abrupt discontinuation of ANCA vasculitis therapy can cause serious disease flares.
- Request a liver function review if you have not had one recently — the FDA's hepatotoxicity data makes this a priority regardless of the retraction situation.
- Ask your specialist about your specific disease activity and whether a transition to an alternative regimen is appropriate in your case.
- Review your current disease activity score with your specialist — patients in remission may have more flexibility in the timing of any potential regimen change than those with active disease.
- Watch for the outcome of the FDA's July 2026 formal hearing — the FDA's final determination will materially affect clinical guidance and will be reported by MedicalDaily.
Cost and Access: What Patients Should Know
Amgen has maintained a patient update page at amgen.com/tavneos-prescribers with current guidance for healthcare providers and patients. Patients whose insurance has already approved Tavneos may continue to fill prescriptions while the FDA's review process is pending.
For patients who may ultimately need to transition to alternative regimens, cyclophosphamide and rituximab — the established standard-of-care drugs for ANCA vasculitis — are available as alternatives. Rituximab is covered by Medicare and most private insurance for ANCA vasculitis with appropriate prior authorization.
The Vasculitis Foundation provides patient support resources, specialist referral assistance, and regular clinical updates for the vasculitis community.
What Happens Next
The FDA's formal hearing on Tavneos is scheduled for July 2026. Following the hearing, the FDA will either finalize the withdrawal proposal, modify the drug's labeling, or require a new confirmatory trial. Each of these outcomes carries different implications for current patients.
Amgen's independent re-adjudication by the Duke Clinical Research Institute will be presented at the hearing; its outcome could influence the FDA's final decision. MedicalDaily will report on the hearing outcome and any subsequent FDA regulatory action on Tavneos.
The Bottom Line
The clinical trial used to approve Tavneos for ANCA-associated vasculitis has been retracted by the New England Journal of Medicine after an FDA investigation found that outcome data for nine patients were altered after the study database was locked. The FDA has proposed withdrawal, the EMA has moved to revoke the EU approval, and a formal FDA hearing is scheduled this month. None of this means patients should stop taking the drug on their own — that decision requires a physician who knows the patient's disease activity, current disease control, and risk-benefit profile. If you take Tavneos, call your specialist.
